Oppenheimer Cuts Price Target on United Rentals (URI) Following 2Q15 Results and Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
RBC Capital Downgrades United Rentals (URI) to Outperform
July 24, 2015 7:05 AM EDTRBC Capital downgraded United Rentals (NYSE: URI) from Top Pick to Outperform with a price target of $94.00 (from $110.00).
For an analyst ratings summary and ratings history on United Rentals click here. For more ratings news on United Rentals click here.
Shares of United Rentals closed at $66.98 yesterday.
... MoreNotable 52-Week Highs and Lows 7/23: (ITEK) (HBAN) (FTNT) High; (URI) (UNP) (CAB) Low
July 23, 2015 3:48 PM EDT52-Week High:Inotek Pharmaceuticals (Nasdaq: ITEK) $16.75. Inotek Pharmaceuticals ripping higher Thursday after the company announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eyes natural pressure control mechanism. Based on feedback from a recent End of Phase 2 meeting with the US Food and Drug Administration (FDA), Inotek is in final preparation stages to commence its first Phase 3 trial to support a New Drug Application (NDA) for trabodenoson.
Pre-Open Stock Movers 07/23: (CARA) (SNDK) (CRUS) Higher; (CVA) (URI) (SCSS) Lower (more...)
July 23, 2015 9:30 AM EDTInotek Pharmaceuticals Corporation (NASDAQ: ITEK) 51% HIGHER; announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eyes natural pressure control mechanism. Based on... More
